Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study

Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Jiro Uehara, Manabu Fujimoto, Tatsuya Takenouchi, Masaki Otsuka, Hiroshi Uchi, Hironobu Ihn, Hironobu Minami

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Treating advanced or recurrent melanoma remains a challenge. Cancer cells can evade the immune system by blocking T-cell activation through overexpression of the inhibitory receptor programmed death 1 (PD-1) ligands. The PD-1 inhibitor nivolumab blocks the inhibitory signal in T cells, thus overcoming the immune resistance of cancer cells. Nivolumab has shown promising anticancer activity in various cancers. We carried out a single-arm, open-label, multicenter, phase II study to investigate the efficacy and safety of nivolumab in previously untreated Japanese patients with advanced melanoma. Twenty-four patients with stage III/IV or recurrent melanoma were enrolled and received i.v. nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint was overall response rate evaluated by an independent radiology review committee. The independent radiology review committee-assessed overall response rate was 34.8% (90% confidence interval, 20.8–51.9), and the overall survival rate at 18 months was 56.5% (90% confidence interval, 38.0–71.4). Treatment-related adverse events (AEs) of grade 3 or 4 only occurred in three patients (12.5%). Two patients discontinued nivolumab because of AEs, but all AEs were considered manageable by early diagnosis and appropriate treatment. Subgroup analyses showed that nivolumab was clinically beneficial and tolerable regardless of BRAF genotype, and that patients with treatment-related select AEs and with vitiligo showed tendency for better survival. In conclusion, nivolumab showed favorable efficacy and safety profiles in Japanese patients with advanced or recurrent melanoma, with or without BRAF mutations. (Trial registration no. JapicCTI-142533.).

Original languageEnglish
Pages (from-to)1223-1230
Number of pages8
JournalCancer Science
Volume108
Issue number6
DOIs
Publication statusPublished - Jun 2017

Fingerprint

Melanoma
Safety
Advisory Committees
Radiology
Confidence Intervals
T-Lymphocytes
Neoplasms
Death Domain Receptors
Vitiligo
nivolumab
Disease Progression
Early Diagnosis
Immune System
Therapeutics
Survival Rate
Genotype
Ligands
Mutation
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yamazaki, N., Kiyohara, Y., Uhara, H., Uehara, J., Fujimoto, M., Takenouchi, T., ... Minami, H. (2017). Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study. Cancer Science, 108(6), 1223-1230. https://doi.org/10.1111/cas.13241

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma : A phase II study. / Yamazaki, Naoya; Kiyohara, Yoshio; Uhara, Hisashi; Uehara, Jiro; Fujimoto, Manabu; Takenouchi, Tatsuya; Otsuka, Masaki; Uchi, Hiroshi; Ihn, Hironobu; Minami, Hironobu.

In: Cancer Science, Vol. 108, No. 6, 06.2017, p. 1223-1230.

Research output: Contribution to journalArticle

Yamazaki, N, Kiyohara, Y, Uhara, H, Uehara, J, Fujimoto, M, Takenouchi, T, Otsuka, M, Uchi, H, Ihn, H & Minami, H 2017, 'Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study', Cancer Science, vol. 108, no. 6, pp. 1223-1230. https://doi.org/10.1111/cas.13241
Yamazaki, Naoya ; Kiyohara, Yoshio ; Uhara, Hisashi ; Uehara, Jiro ; Fujimoto, Manabu ; Takenouchi, Tatsuya ; Otsuka, Masaki ; Uchi, Hiroshi ; Ihn, Hironobu ; Minami, Hironobu. / Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma : A phase II study. In: Cancer Science. 2017 ; Vol. 108, No. 6. pp. 1223-1230.
@article{fd8f3b84dc5c44c2a4296132799d921f,
title = "Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study",
abstract = "Treating advanced or recurrent melanoma remains a challenge. Cancer cells can evade the immune system by blocking T-cell activation through overexpression of the inhibitory receptor programmed death 1 (PD-1) ligands. The PD-1 inhibitor nivolumab blocks the inhibitory signal in T cells, thus overcoming the immune resistance of cancer cells. Nivolumab has shown promising anticancer activity in various cancers. We carried out a single-arm, open-label, multicenter, phase II study to investigate the efficacy and safety of nivolumab in previously untreated Japanese patients with advanced melanoma. Twenty-four patients with stage III/IV or recurrent melanoma were enrolled and received i.v. nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint was overall response rate evaluated by an independent radiology review committee. The independent radiology review committee-assessed overall response rate was 34.8{\%} (90{\%} confidence interval, 20.8–51.9), and the overall survival rate at 18 months was 56.5{\%} (90{\%} confidence interval, 38.0–71.4). Treatment-related adverse events (AEs) of grade 3 or 4 only occurred in three patients (12.5{\%}). Two patients discontinued nivolumab because of AEs, but all AEs were considered manageable by early diagnosis and appropriate treatment. Subgroup analyses showed that nivolumab was clinically beneficial and tolerable regardless of BRAF genotype, and that patients with treatment-related select AEs and with vitiligo showed tendency for better survival. In conclusion, nivolumab showed favorable efficacy and safety profiles in Japanese patients with advanced or recurrent melanoma, with or without BRAF mutations. (Trial registration no. JapicCTI-142533.).",
author = "Naoya Yamazaki and Yoshio Kiyohara and Hisashi Uhara and Jiro Uehara and Manabu Fujimoto and Tatsuya Takenouchi and Masaki Otsuka and Hiroshi Uchi and Hironobu Ihn and Hironobu Minami",
year = "2017",
month = "6",
doi = "10.1111/cas.13241",
language = "English",
volume = "108",
pages = "1223--1230",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma

T2 - A phase II study

AU - Yamazaki, Naoya

AU - Kiyohara, Yoshio

AU - Uhara, Hisashi

AU - Uehara, Jiro

AU - Fujimoto, Manabu

AU - Takenouchi, Tatsuya

AU - Otsuka, Masaki

AU - Uchi, Hiroshi

AU - Ihn, Hironobu

AU - Minami, Hironobu

PY - 2017/6

Y1 - 2017/6

N2 - Treating advanced or recurrent melanoma remains a challenge. Cancer cells can evade the immune system by blocking T-cell activation through overexpression of the inhibitory receptor programmed death 1 (PD-1) ligands. The PD-1 inhibitor nivolumab blocks the inhibitory signal in T cells, thus overcoming the immune resistance of cancer cells. Nivolumab has shown promising anticancer activity in various cancers. We carried out a single-arm, open-label, multicenter, phase II study to investigate the efficacy and safety of nivolumab in previously untreated Japanese patients with advanced melanoma. Twenty-four patients with stage III/IV or recurrent melanoma were enrolled and received i.v. nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint was overall response rate evaluated by an independent radiology review committee. The independent radiology review committee-assessed overall response rate was 34.8% (90% confidence interval, 20.8–51.9), and the overall survival rate at 18 months was 56.5% (90% confidence interval, 38.0–71.4). Treatment-related adverse events (AEs) of grade 3 or 4 only occurred in three patients (12.5%). Two patients discontinued nivolumab because of AEs, but all AEs were considered manageable by early diagnosis and appropriate treatment. Subgroup analyses showed that nivolumab was clinically beneficial and tolerable regardless of BRAF genotype, and that patients with treatment-related select AEs and with vitiligo showed tendency for better survival. In conclusion, nivolumab showed favorable efficacy and safety profiles in Japanese patients with advanced or recurrent melanoma, with or without BRAF mutations. (Trial registration no. JapicCTI-142533.).

AB - Treating advanced or recurrent melanoma remains a challenge. Cancer cells can evade the immune system by blocking T-cell activation through overexpression of the inhibitory receptor programmed death 1 (PD-1) ligands. The PD-1 inhibitor nivolumab blocks the inhibitory signal in T cells, thus overcoming the immune resistance of cancer cells. Nivolumab has shown promising anticancer activity in various cancers. We carried out a single-arm, open-label, multicenter, phase II study to investigate the efficacy and safety of nivolumab in previously untreated Japanese patients with advanced melanoma. Twenty-four patients with stage III/IV or recurrent melanoma were enrolled and received i.v. nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint was overall response rate evaluated by an independent radiology review committee. The independent radiology review committee-assessed overall response rate was 34.8% (90% confidence interval, 20.8–51.9), and the overall survival rate at 18 months was 56.5% (90% confidence interval, 38.0–71.4). Treatment-related adverse events (AEs) of grade 3 or 4 only occurred in three patients (12.5%). Two patients discontinued nivolumab because of AEs, but all AEs were considered manageable by early diagnosis and appropriate treatment. Subgroup analyses showed that nivolumab was clinically beneficial and tolerable regardless of BRAF genotype, and that patients with treatment-related select AEs and with vitiligo showed tendency for better survival. In conclusion, nivolumab showed favorable efficacy and safety profiles in Japanese patients with advanced or recurrent melanoma, with or without BRAF mutations. (Trial registration no. JapicCTI-142533.).

UR - http://www.scopus.com/inward/record.url?scp=85021175906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021175906&partnerID=8YFLogxK

U2 - 10.1111/cas.13241

DO - 10.1111/cas.13241

M3 - Article

C2 - 28342215

AN - SCOPUS:85021175906

VL - 108

SP - 1223

EP - 1230

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 6

ER -